Sugi Predict

Sugi Predict / Targets / S1PR3

S1PR3

Sphingosine 1-phosphate receptor 3 · Q99500 · S1PR3 on Sugi Atlas →

165,168 patent compounds predicted against S1PR3, 81,718 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL36337 SCHEMBL36337 0.87 20/20
SCHEMBL35831 SCHEMBL35831 0.74 20/20
SCHEMBL35626 SCHEMBL35626 0.71 20/20
SCHEMBL35942 SCHEMBL35942 0.71 20/20
SCHEMBL36170 SCHEMBL36170 0.71 20/20
SCHEMBL35933 SCHEMBL35933 0.67 20/20
SCHEMBL36123 SCHEMBL36123 0.66 20/20
SCHEMBL36206 SCHEMBL36206 0.66 20/20
SCHEMBL35848 SCHEMBL35848 0.63 20/20
SCHEMBL35951 SCHEMBL35951 0.63 20/20
SCHEMBL36013 SCHEMBL36013 0.63 20/20
SCHEMBL35944 SCHEMBL35944 0.59 20/20
SCHEMBL36110 SCHEMBL36110 0.59 20/20
SCHEMBL36045 SCHEMBL36045 0.59 20/20
SCHEMBL36218 SCHEMBL36218 0.55 20/20
SCHEMBL35789 SCHEMBL35789 0.61 19/20
SCHEMBL36162 SCHEMBL36162 0.60 18/20
SCHEMBL35623 SCHEMBL35623 0.59 18/20
SCHEMBL36231 SCHEMBL36231 0.85 17/20
SCHEMBL35846 SCHEMBL35846 0.67 17/20

Clinical trials — most relevant to S1PR3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Sphingosine-1-phosphate and Pneumonia PHASE2/PHASE3UNKNOWN
Repurposing Siponimod for Alzheimer's Disease PHASE2RECRUITING
Fingolimod in Schizophrenia Patients PHASE2COMPLETED
Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) PHASE2WITHDRAWN
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation PHASE2ENROLLING_BY_INVITATION
Efficacy and Safety of FTY720 for Acute Stroke PHASE2COMPLETED
Lovaza's Effect on the Activation of Platelets PHASE2COMPLETED
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. PHASE1COMPLETED
Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration PHASE1UNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod nanCOMPLETED
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study nanUNKNOWN
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma nanSUSPENDED
Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis nanUNKNOWN
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness nanUNKNOWN
Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain nanUNKNOWN
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure nanCOMPLETED
Evaluation of Serum Ceramides C16, C24, and Sphingosine-1-Phosphate (S1P) in Patients With Acne Vulgaris nanNOT_YET_RECRUITING
Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720) nanUNKNOWN
Effect of Plasma Ceramides on Peripheral Vascular Function nanCOMPLETED
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS) nanCOMPLETED
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma nanRECRUITING
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes nanCOMPLETED
Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention nanUNKNOWN
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2 nanCOMPLETED
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales nanRECRUITING
COVID-19 Vaccine Response in Treated MS Patients nanCOMPLETED
Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a S1PR3 binder may also engage these)

ProteinNameSimilarity
Q9Z0U9 — 0.999 Q9Z0U9 →
Q9PUQ8 — 0.996 Q9PUQ8 →
Q9DDK4 — 0.991 Q9DDK4 →
S1PR1 Sphingosine 1-phosphate receptor 1 0.987 landscape →
O08530 — 0.984 O08530 →
Q5E9P3 — 0.984 Q5E9P3 →
P48303 — 0.983 P48303 →
P47752 — 0.966 P47752 →
P60894 — 0.966 P60894 →
O02777 — 0.966 O02777 →
P47746 — 0.965 P47746 →
Q98894 — 0.965 Q98894 →
P60893 — 0.965 P60893 →
Q5RBG7 — 0.962 Q5RBG7 →
P52592 — 0.962 P52592 →
P20272 — 0.962 P20272 →
P60895 — 0.961 P60895 →
S1PR2 Sphingosine 1-phosphate receptor 2 0.961 landscape →
Q98895 — 0.961 Q98895 →
Q71SP5 — 0.961 Q71SP5 →
P56971 — 0.959 P56971 →
Q5IS73 — 0.959 Q5IS73 →
Q9I919 — 0.958 Q9I919 →
Q333S9 — 0.958 Q333S9 →
Q9PUI7 — 0.957 Q9PUI7 →
CNR2 Cannabinoid receptor 2 0.956 landscape →
Q9I918 — 0.956 Q9I918 →
Q9EQQ3 — 0.955 Q9EQQ3 →
PTGFR Prostaglandin F2-alpha receptor 0.955 landscape →
Q5E9H8 — 0.955 Q5E9H8 →